Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15594545 | 0.86 | MAPT (0.55) | MAPTNPC1POLBGPBAR1MEN1 | |
| SCHEMBL15043768 | 0.84 | MAPT (0.57) | MAPTNPC1POLBGPBAR1RBP4 | |
| SCHEMBL7232612 | 0.83 | MAPT (0.56) | MAPTNPC1POLBGPBAR1RBP4 | |
| SCHEMBL15594598 | 0.83 | MAPT (0.55) | MAPTNPC1POLBGPBAR1MEN1 | |
| SCHEMBL15594536 | 0.82 | MAPT (0.51) | MAPTNPC1POLBGPBAR1MEN1 | |
| SCHEMBL4419942 | 0.82 | MAPT (0.51) | MAPTNPC1POLBGPBAR1KMT2A | |
| SCHEMBL15594583 | 0.82 | MAPT (0.51) | MAPTNPC1POLBGPBAR1MLYCD | |
| SCHEMBL25214530 | 0.82 | MAPT (0.55) | MAPTNPC1POLBGPBAR1RBP4 | |
| SCHEMBL4421335 | 0.82 | MAPT (0.51) | MAPTNPC1POLBGPBAR1MEN1 | |
| SCHEMBL9018164 | 0.81 | MAPT (0.54) | MAPTNPC1POLBGPBAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2723717-A2 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012177893-A2 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177893-A2 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-6566518-B1 | Pesticides, especially suitable for controlling sucking insects, especially of the order Homoptera, preferably for controlling these pests in vegetable, fruit, rice and cotton crops; systemic action. | SYNGENTA CROP PROTECTION, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1200413-A1 | TRIFLUOROMETHYLPYRI(MI)DINE CARBOXAMIDES | Syngenta Participations AG (CH) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009104-A1 | TRIFLUOROMETHYLPYRI(MI)DINE CARBOXAMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | MAPT 800/4885NPC1 533/4885POLB 4413/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | MAPT 800/4885NPC1 533/4885POLB 4413/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | MAPT 800/4885NPC1 533/4885POLB 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.